ACIP General Best Practices Updates (Harmonization with ACIP Vaccine-Specific Recommendations)

["Centers for Disease Control and Prevention" <no-reply@xxxxxxxxxxxxxxxxxxxx>]

You are subscribed to one or more of the following CDC subscription topics. 

• Advisory Committee on Immunization Practices (ACIP)
• ACIP Vaccine Recommendations and Guidelines
• Healthcare Providers/Professionals
• For Immunization Managers
  

Updates as of February 21, 2020

• PAGE 23 [38 pages]
  Timing and Spacing of Immunobiologics
  The recommendation was changed to allow providers to administer a dose of live, injectable vaccine even if the interval after an antibody-containing blood product is not complete. The dose should be invalidated and repeated. Serology is no longer recommended to ascertain whether the dose provided protection.
• PAGE 39 [38 pages]
  Timing and Spacing of Immunobiologics
  Table 3-5 Footnotes
  The specific source material for understanding antibody quantities in antibody products is now listed. Also listed is the process for determining how to calculate the interval between antibody product and live, injectable vaccine, based on the quantity of antibody in the product.
• PAGE 55 [19 pages]
  Contraindications and Precautions
  Table 4-1
  A footnote is placed after HPV vaccine to clarify that HPV vaccine is not recommended during pregnancy.
• PAGE 115 [6 pages]
  Storage and Handling of Immunobiologics
  For response to out-of-range temperature readings, if a non-live vaccine is administered and then found out to have been stored at a deviated temperature, the dose should be repeated and does not need to wait an interval from the invalid dose. Shingrix is a non-live vaccine, this dose needs to be repeated and does need to wait 4 weeks after the invalid dose.